Viridian Therapeutics, Inc. (VRDN): Total Liabilities
$177.25M
As of 2025-12-31
$435.14M
As of 2026-06-30
+64.2%
3-year compound annual growth
+73.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $177.25M | +150.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $70.76M | +46.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $48.40M | +20.9% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $40.03M | +150.3% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $15.99M | +42.6% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $11.22M | -22.7% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $14.51M | -2.0% | 2021-03-26, Balance as of period end |
| 2018-12-31 | $14.80M | +6.0% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $13.97M | +44.0% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $9.71M | n/a | 2018-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $107.62M | -34.3% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
Compare VRDN, ASMB, RMTI, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗